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A B S T R A C T
Opioid overdoses, many of which are attributed to use of illicit fentanyl, are currently one of the leading causes
of death in the U.S. Although fentanyl has been used safely for decades in clinical settings, the widespread use of
illicit fentanyl is a recent phenomenon. Starting in 2013, illicitly manufactured fentanyl and its analogs began to
appear on the streets. These substances were added to or sold as heroin, often unbeknownst to the user. Because
fentanyl is so potent, only small amounts are needed to produce pharmacological effects, but the margin between
safe and toxic doses is narrow. Surprisingly little is known about the exact signaling mechanisms underlying
fentanyl-related respiratory depression or the effectiveness of naloxone in reversing this effect. Similarly, little is
known about the ability of treatment medications such as buprenorphine, methadone, or naltrexone to reduce
illicit fentanyl use. The present article reviews the receptor, preclinical and clinical pharmacology of fentanyl,
and how its pharmacology may predict the effectiveness of currently approved medications for treating illicit
fentanyl use.
1. Introduction: development of fentanyl
Paul Janssen synthesized fentanyl in 1960 with the rationale that
synthesis of a highly potent drug with increased receptor specificity
would exhibit a greater safety profile compared to morphine (Stanley,
1992; 2008). It was approved initially in the United States only as a
combination medication with droperidol because of concerns about its
extreme potency and greater propensity to produce muscle rigidity
compared to other opioids. Despite these early concerns, the ability of
fentanyl to provide cardiovascular stability and to block the stress re-
sponse to surgical stimuli at high doses made it the mainstay of cardiac
anesthesia. The clinical use of fentanyl was restricted to anesthesia until
the 1990s when the development of non-injectable formulations was
pursued. Today, numerous fentanyl-alone products are approved for
use in the U.S. including oral transmucosal lozenges, effervescent
buccal tablets, sublingual tablets, sublingual sprays, nasal sprays,
transdermal patches, and injectable formulations. These products are
used as anesthetic agents in surgical settings, treatments for chronic
pain, and supplemental medications for breakthrough pain in patients
with cancer (DEA, 2016). A number of other medications with chemical
structures similar to fentanyl have been synthesized (e.g., sufentanil,
alfentanil, and carfentanil), which are restricted for use in clinical an-
esthesia or more uncommonly used as nerve blocks, or, in the case of
carfentanil, as a radiotracer in research studies using positron emission
tomography (PET). These medications are substantially more potent
than morphine: for example, carfentanil is 10,000 times more potent
than morphine as an analgesic.
2. Epidemiology of illicit fentanyl use
Despite the current widespread use of fentanyl in clinical settings,
an additional concern that delayed its initial approval in the U.S. was its
potential for abuse (Stanley et al., 2008). The U.S. Drug Enforcement
Agency eventually placed fentanyl, as well as the other fentanyl-like
medications including sufentanil, alfentanil, and carfentanil into Sche-
dule II of the Controlled Substances Act because it was believed that
they had high potential for abuse. For decades after approval of fen-
tanyl, however, reports of its abuse were low compared to other pre-
scription opioid products, such as oxycodone and hydrocodone (Cicero
et al., 2005; Katz et al., 2008). Most of the early reports suggested that
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fentanyl was being abused by healthcare professionals, such as an-
esthesiologists, who had easy access to it (e.g., Knisely et al., 2002;
Silsby et al., 1984; Ward et al., 1983). Although later reports described
non-medical use of the fentanyl transdermal patch by patients and/or
individuals with substance use disorders (Jumbelic, 2010), overall
prevalence rates of non-medical use of FDA-approved fentanyl products
remained low. But in 2006, a surge in fentanyl-related overdose deaths
and Drug Enforcement Agency (DEA) seizures of illicitly manufactured
fentanyl occurred in the U.S. This “crisis” was attributed to fentanyl
being mixed into heroin (Drug Enforcement Administration, 2016). The
origin of this crisis was traced to a single clandestine laboratory that
was manufacturing fentanyl illicitly, and when the laboratory was shut
down, fentanyl overdose deaths and DEA seizures of fentanyl rapidly
declined.
In the current fentanyl crisis, multiple clandestine laboratories
around the world are manufacturing illicit fentanyl as well as a number
of other compounds with similar chemical structures that until very
recently would have eluded DEA scheduling but now is covered under a
derivative law to prevent evasion of prosecution (Pichini et al., 2018).
Beginning in 2013, a dramatic increase in fentanyl seizures occurred in
the U.S.A. and by 2015, the number of fentanyl seizures was approxi-
mately 8 times higher than in 2006 (DEA Intelligence Brief, 2006).
Synthesis of fentanyl is relatively straightforward compared to heroin,
and because it is so potent, fentanyl is easy to conceal and transport for
sale, so the risks to drug dealers of detection and arrest are reduced. It is
purchased by dealers at low cost and added to heroin without the user’s
knowledge, which results in enormous profits for the dealer. In addition
to being used as an adulterant to heroin, fentanyl is being sold in pill
form as counterfeit Norco®, a prescription pain medication containing
hydrocodone and acetaminophen (DEA Intelligence Brief DEA-DCT-
DIB-021-16, 2016), or CDN 80, which is meant to mimic a prescription
pain medication containing oxycodone that is sold in Canada (European
Monitoring Centre for Drugs and Drug Addiction, 2017). Of equal or
greater concern is that fentanyl is being added to cocaine and sold as
counterfeit Xanax® pills (a short-acting benzodiazepine anxiolytic used
to treat anxiety disorders; DEA Intelligence Brief DEA-DCT-DIB-021-16,
2016). Because users of these substances typically have little or no
tolerance to opioids, the risk of overdose may be higher. The tre-
mendous rise in availability of illicit fentanyl has been associated with a
rise in overdose deaths. More than 63,000 Americans died of drug
overdoses in 2016, over 19,000 of which were related to synthetic
opioids such as fentanyl and its analogs (https://www.cdc.gov/
drugoverdose/data/statedeaths.html and https://www.cdc.gov/
drugoverdose/data/fentanyl.html; accessed October 15, 2018). The
concern is that the numbers of overdoses and deaths due to fentanyl
will continue to increase in the coming years. Despite these alarming
trends, relatively little is known about the exact signaling mechanisms
that contribute to fentanyl-related overdose and death, and how ef-
fective current FDA-approved treatment medications for opioid use
disorder may be against fentanyl. Subsequent sections of this review
will describe the receptor pharmacology of fentanyl, the preclinical
data on its abuse liability, the clinical pharmacology of fentanyl as it
relates to abuse liability, and their implications for treatment of fen-
tanyl abuse.
3. Fentanyl pharmacology
Like most clinically used opioids, fentanyl produces its pharmaco-
logical effects via activation of the mu opioid receptor (MOR) with low
affinity for delta and kappa opioid receptors. Fentanyl is a synthetic,
lipophilic phenylpiperidine opioid agonist, unlike morphine, which is
an alkaloid extracted from the opium poppy. Fentanyl is a highly effi-
cacious agonist at the MOR with a 1.35 nM binding affinity (Ki) at re-
combinant human MORs (Volpe et al., 2011), an affinity similar to that
reported using guinea pig membranes (1.2 nM Ki; Maguire et al., 1992).
Albeit, a wide range of fentanyl binding affinities for the MOR have
been reported (Ki= 0.007 (Chen et al., 1993) to> 200 nM (Traynor
and Nahorski, 1995)), which most likely reflects differences in the
radioligand, species, assay, or tissue used. This affinity is very similar to
morphine binding at the MOR (Ki= 1.17 nM). Additionally, the elim-
ination/clearance half-life is similar between fentanyl and morphine
with t1/2 of 2–4 h for fentanyl and 2 h for morphine. This may be sur-
prising, considering that fentanyl has a faster onset, much shorter
duration of analgesic action, and higher analgesic potency compared to
morphine. Human and preclinical studies show that fentanyl is 50 times
(intramuscular), 150 times (subcutaneous), ∼400 times (intravenous)
or 10 times (epidural) more potent than morphine (Finch and
DeKornfeld, 1967; Terenius, 1974; van den Hoogen and Colpaert,
1987), but most physicians accept and conversion charts report that
fentanyl is approximately 100 times more potent than morphine. Ad-
ditionally, fentanyl rapidly crosses the blood-brain barrier, resulting in
greater analgesic potency, which is reflected in a half-life of∼5min for
equilibrium between plasma and cerebrospinal fluid. Thus, the greater
analgesic potency and faster onset of fentanyl compared to morphine is
not explained by binding affinity or half-life. Fentanyl levels rapidly
decline due to redistribution to other tissues and fentanyl has rapid
sequestration into body fat, contributing to its short duration of action.
The difference in potency and onset and duration of action is, in part,
attributed to the differential lipophilicity of these drugs. Of the clini-
cally available MOR agonists, fentanyl and sufentanil are the most lipid
soluble, whereas morphine is more hydrophilic. Using a classical oc-
tanol-water partition coefficient to measure lipid solubility, the co-ef-
ficient for morphine is 6 but> 700 for fentanyl (Lötsch et al., 2013).
The difference in lipid solubility impacts not only the route of admin-
istration for clinical use but also the pharmacokinetics of metabolism
and elimination. Additionally, the pharmacokinetic properties of fen-
tanyl allowed for the development of unique clinical indications of non-
injectable formulations ranging from treatment of cancer breakthrough
pain using nasal formulations with direct access to the brain to trans-
dermal release for treating chronic pain.
Fentanyl is poorly absorbed from the gastrointestinal tract but is
exclusively metabolized where renal excretion accounts for less than
10% of the dose. Metabolism by piperidine N-dealkylation to norfen-
tanyl, an inactive metabolite, is the predominant degradative pathway
in humans, accounting for 99% of fentanyl metabolism (Labroo et al.,
1997). Fentanyl metabolism is mediated almost exclusively by cyto-
chrome P450 CYP3A4, together with CYP3A5 and CYP3A7 (Labroo
et al., 1997). The involvement of CYP3A-dependent metabolism ac-
counts for many adverse drug interactions, including the HIV protease
inhibitor ritonavir (Olkkola et al., 1999). Ritonavir and the calcium
channel blocker diltiazem have been reported to increase plasma levels
and reduce elimination of fentanyl. Conversely, fentanyl can act as an
enzyme inhibitor and reduce the clearance of sedative drugs such as
midazolam. The short duration of action is in part due to the activity of
P-glycoproteins within the blood-brain barrier that pumps fentanyl out
of the central nervous system (CNS) (Wandel et al., 2002; Ziesenitz and
van den Anker, 2013). The importance of these proteins is evident in
that loperamide, an opioid used for treatment of diarrhea has negligible
CNS effects, but this peripheral restriction is solely due to its high af-
finity for the P-glycoprotein substrate (Schinkel et al., 1996); loper-
amide produces CNS effects in P-glycoprotein knockout rodents (Tatke
et al., 2018). Genetic polymorphisms in the ABCB1 gene that encodes
for the P-glycoproteins (ABCB1 1236 T T (rs1128503), 2677 T T
(rs2032582) and 3435 T T (rs1045642)) causes CNS retention of fen-
tanyl (Lötsch et al., 2013), resulting in adverse effects such as re-
spiratory depression and sedation (Kesimci et al., 2012; Takashina
et al., 2012). The ability of opioids to produce differential effects on
nociception, respiratory depression, and constipation likely results from
a combination of their chemistry, which will affect their distribution
within the central nervous system, metabolism, receptor selectivity and
receptor signaling.
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4. Preclinical pharmacology of fentanyl
MOR belong to the superfamily of G-protein coupled receptors, a
class of membrane-bound receptors that exhibit a seven transmem-
brane-spanning helical domain connected by intra- and extra-cellular
loops. The MOR produces its effects via interactions with inhibitory
heterotrimeric G-proteins (Gi/o), which are responsible for producing
most opioid-related pharmacological effects, including analgesia and
euphoria. However, MOR also produce G-protein-independent signaling
through beta-arrestin complexes. A concerted effort is now underway to
identify ligands with a bias towards G-protein signaling with less acti-
vation of beta-arrestins, as the arrestin signaling has been proposed to
account for the life-threatening respiratory depressive effects of opioids
(Fig. 1A, Groer et al., 2007; Manglik et al., 2016; Schmid et al., 2017;
Schneider et al., 2016). A biased agonist is defined by the ability of
agonist binding to the same receptor to differentially activate signaling
cascades that results in the formation of different protein complexes
that trigger different downstream cellular events. The beta-arrestin-2
knockout mouse is protected from morphine-induced respiratory de-
pression and acute constipation (Raehal et al., 2005), although an-
algesic effects are enhanced by the absence of beta-arrestin 2 (Bohn
et al., 1999). A spectrum of signaling bias for different opioid drugs was
recently reviewed (Williams et al., 2013). Fentanyl exhibits signaling
bias with greater arrestin relative to G-protein signaling, as measured
Fig. 1. A. Pharmacological differences between fen-
tanyl and prototypical opioid agonist morphine.
Morphine binds to mu opioid receptors (MOR) and
primarily produces signaling through activation of G-
proteins, whereas fentanyl also activates beta-arrestin
pathways that leads to respiratory depression. The
enhanced respiratory depression of fentanyl compared
to morphine may be due to their differences in in-
tracellular signaling cascades. *Please note that equi-
analgesic conversion is dependent on route of admin-
istration and species. Opioid exposure prior to in-
tracranial self-stimulation (ICSS) (B) or intravenous
self-administration (IVSA) (C) produces activity pre-
dictive of increasing abuse potential. In contrast, pain
prior to ICSS (B) or IVSA (C) has the opposite effect,
where abuse potential is reduced. Note, the reduced
abuse potential with prior pain to opioid exposure may
not apply to individuals with comorbidities of post-
traumatic stress disorder, depression and anxiety or
the presence of catastrophizing (Evans & Cahill, 2016).
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by GTPγS binding in cells expressing mouse or human MORs (Schmid
et al., 2017). This effect is evident in striatal neurons, where acute
administration of fentanyl activates the mitogen-activated protein ki-
nase (MAP kinase) ERK1/2 in a beta-arrestin-dependent manner, an
effect that is absent following acute morphine (Macey et al., 2006),
although ERK1/2 activation is produced following chronic morphine
(Bilecki et al., 2005; Ligeza et al., 2008). In cell culture experiments,
fentanyl promotes robust receptor phosphorylation, beta-arrestin-2 re-
cruitment and receptor internalization but morphine has much weaker
effects on these parameters. Perhaps surprising given the agonist bias of
fentanyl for beta-arrestin signaling is that analgesic tolerance to fen-
tanyl is not perturbed in beta-arrestin-2 knockout mice (Raehal and
Bohn, 2011), whereas morphine tolerance is attenuated (Bohn et al.,
2000). The above discussion specifically relates to differences between
fentanyl and morphine, but comprehensive reviews of mechanisms
underlying the development and maintenance of opioid tolerance have
been published previously (Morgan and Christie, 2011; Williams et al.,
2013).
Fentanyl is a highly efficacious MOR agonist that results in less
analgesic tolerance than lower efficacy MOR agonists such as morphine
(Williams et al., 2013), although greater analgesic tolerance to fentanyl
was reported following chronic administration in models of chronic
pain (Imai et al., 2006; Narita et al., 2013). Fentanyl produces short-
term tolerance (measured using a phasic thermal tail flick test) through
a G-protein receptor kinase-dependent (GRK3) mechanism, whereas
morphine produces tolerance through a c-Jun N-terminal kinase-de-
pendent mechanism and not GRK3 (Terman et al., 2004; Kuhar et al.,
2015). Similarly, beta-arrestin-2-dependent JNK cascade signaling was
responsible for morphine analgesic tolerance and locomotor sensitiza-
tion but not that of fentanyl (Mittal et al., 2012). Many studies have
demonstrated that fentanyl and morphine differ with regard to me-
chanisms of opioid tolerance and reinforcing effects. For example,
RGS9-2, a regulator of G-protein signaling, binds to the activated Gα
subunit of G-proteins, thereby controlling MOR signal transduction,
desensitization, analgesic tolerance and physical dependence. Knockout
of RGS9-2 protein decreases fentanyl- but increases morphine-induced
acute analgesia (Psifogeorgou et al., 2011). Additionally, a MOR poly-
morphism OPRM1 A118 G (using a humanized mouse model) reduces
the ability of morphine to potentiate intracranial self-administration
(ICSS, a positively reinforced operant behavior in which lever-press
responding is maintained by delivery of electrical brain stimulation and
is a hallmark of abuse potential) of the medial forebrain bundle and
depresses morphine-induced dopamine release (implicated in reward).
However, this polymorphism has no effect on fentanyl-induced ICSS or
dopamine release (Robinson et al., 2015). Another point mutation
T394 A at the MOR T394 phosphorylation site decreased opioid an-
algesic tolerance but increased intravenous heroin self-administration
and dopamine release in the nucleus accumbens, suggesting that this
mutation may increase susceptibility to opioid abuse (Wang et al.,
2016).
There still exists a great debate over the influence of pain on the
abuse potential of opioid analgesics. In pain models, a depression of
ICSS is thought to capture the affective dimension of pain (Negus,
2013). In contrast to a chronic neuropathic pain model, acute visceral
pain induced by intraperitoneal injection of lactic acid depressed ICSS
(Ewan and Martin, 2011b; Altarifi et al., 2015). Systemic injection of a
high-efficacy agonist such as fentanyl was more potent at blocking the
depression of ICSS caused by an acute pain stimulus (Altarifi et al.,
2015). In a model of chronic neuropathic pain, fentanyl, methadone
and hydromorphone were less potent in facilitating ICSS (when elec-
trical stimulation was in the ventral tegmental area) compared to pain-
naïve controls, which was interpreted to reflect diminished abuse po-
tential of opioids in chronic pain states (Fig. 1B, Ewan and Martin,
2011b). A previous study reported similar findings for heroin (Ewan
and Martin, 2011a). Interestingly, morphine failed to facilitate ICSS in
the presence of chronic neuropathic pain (Ewan and Martin, 2011b) or
in an acute model of acute visceral pain (Altarifi et al., 2015).
Drug self-administration is more commonly used to measure re-
inforcing effects of drugs. Seminal studies examining the influence of
chronic pain on opioid self-administration identified that the acquisi-
tion of heroin, morphine, fentanyl, hydromorphone and methadone
self-administration was significantly reduced in the presence of chronic
pain compared to sham control surgery, but there was no effect on
responding for food (Fig. 1C, Martin et al., 2007). Importantly, the rate
of drug intake correlated with reversal of mechanical allodynia (Martin
et al., 2007). These data are consistent with reports that chronic in-
flammatory pain reduces acquisition of intravenous morphine self-ad-
ministration (Lyness et al., 1989). Similarly, oral fentanyl self-admin-
istration was reduced or absent in three mouse models of chronic pain
induced by complete Freund’s adjuvant inflammatory pain, spinal nerve
ligation for neuropathic pain or a vincristine-induced neuropathy
(Wade et al., 2013). Supporting the hypothesis that pain negatively
influences the abuse potential of opioid analgesics are reports that non-
contingent delivery of analgesics such as indomethacin (Lyness et al.,
1989) or dexamethasone (Colpaert et al., 2001) decreased intravenous
morphine or oral fentanyl self-administration, respectively. However,
others have reported an increase in oral fentanyl consumption in a
model of polyarthritis compared to pain-free or chronic neuropathic
pain in rats (Kupers and Gybels, 1995). In contrast, intravenous heroin
intake was increased if pain was induced after rodents were already
dependent on opioids (Hipólito et al., 2015), which is consistent with
clinical studies showing that patients with chronic pain had an in-
creased risk of opioid analgesic misuse if they had a history of substance
abuse, current high alcohol intake, long-term benzodiazepine use, or
aberrant drug-related behavior (Fishbain et al., 2008; Højsted et al.,
2013; Cragg et al., 2017; Hah et al., 2017). In non-pain conditions,
rodents and non-human primates with extended access to intravenous
heroin self-administration rapidly escalate their drug intake that is
concomitant with development of analgesic tolerance and continued
drug intake despite adverse consequences such as foot shock (Bozarth
and Wise, 1985; Ahmed et al., 2000; Chen et al., 2006; Negus, 2006;
Wade et al., 2015).
5. Clinical pharmacology of fentanyl: focus on abuse potential
5.1. Healthy volunteers
Some of the early studies of the abuse liability of fentanyl were
conducted in normal, healthy volunteers who did not use drugs re-
creationally, although most of the participants used alcohol occasion-
ally. In this population, fentanyl did not reliably increase positive
subjective responses. At intravenous (i.v.) doses up to approximately
250 μg/70 kg, fentanyl increased positive subjective effects in 4 studies
(e.g., it increased ratings of euphoria, feelings of well-being, or plea-
santness of drug effects in Hoehe, 1988; Hoehe et al., 1988; Manner
et al., 1987; and Matussek and Hoehe, 1989). In 3 other studies as-
sessing i.v. fentanyl doses ranging between 50 μg/70 kg and approxi-
mately 200 μg/70 kg, fentanyl did not increase positive subjective re-
sponses (Ghoneim et al., 1975; Scamman et al., 1984; Zacny et al.,
1996a), and in 2 additional studies, the positive subjective effects
produced by fentanyl were equivocal (Zacny et al., 1992a, b). The ne-
gative findings reported by Ghoneim et al. (1975) and Scamman et al.
(1984) were possibly due to the fact that the peak effects of fentanyl
were missed because measurements of subjective responses did not
begin until 30min after drug administration. Zacny et al. (1996a) re-
ported that participants did report feeling “high” and “coasting (spaced
out)” after receiving 100 μg/70 kg i.v. fentanyl, but ratings of drug
liking did not significantly differ from i.v. saline. In one of the 2 studies
reporting equivocal results (Zacny et al., 1992a), ratings of drug liking
were transient and did not coincide with increased scores on the Mor-
phine-Benzedrine Group (MBG) scale of the Addiction Research Center
Inventory (ARCI), a measure widely used at the time to assess drug-
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induced euphoria. In the other study reporting equivocal results (Zacny
et al., 1992b), only a subset of participants (4 out of 6) reported liking
the effects of fentanyl, but a relatively low dose was tested (50 μg/70 kg
i.v.), so this outcome may not be entirely surprising.
5.2. Illicit opioid users – subjective effects
By current standards, most assessments of the abuse liability of
drugs are conducted in individuals who use them recreationally (Balster
and Bigelow, 2003; Comer et al., 2012; Griffiths et al., 2003). It is
generally assumed that recreational drug users are the most appropriate
population for testing the abuse liability of drugs because by their be-
havior, these individuals have demonstrated that they can recognize
drug effects and they like them, typically at doses that are higher than
those used therapeutically. In 2017, the U.S. Food and Drug Adminis-
tration (FDA) issued a guidance document for industry that re-
commended that recreational drug users who have a recent history of
using substances in the same drug class as the test compound be en-
rolled to assess the abuse liability of drugs. The FDA specifically stated
in their guidance document that “It is not recommended that drug-
naïve subjects be used in HAP [human abuse potential] studies because
this population has not been validated scientifically as being able to
provide accurate information on the abuse potential of a drug.”
Supporting this recommendation is the fact that all of the studies
that examined the subjective effects of fentanyl in experienced drug
users have shown that fentanyl produces clear and dose-related in-
creases in ratings of drug liking, good drug effects, and high (Baylon
et al., 2000; Comer et al., 2008; Greenwald et al., 1996, 2005). Parti-
cipants who were maintained on morphine (30mg orally, given 4 times
per day) reported that they would pay $8.50 for a fentanyl dose of 250
μg/70 kg i.v. compared to $2.50 for saline, and ratings of “bad drug
effects” and “nauseated” were not significantly different from saline
(Comer et al., 2008). Consistent with these results, doses up to 4.5 μg/
kg (∼315 μg/70 kg) did not significantly increase ratings of “bad ef-
fects” or “sick” in non-dependent recreational opioid users (Baylon
et al., 2000). In contrast, 7 out of 8 healthy volunteers who received 3
μg/kg (∼210 μg/70 kg) experienced nausea and 4 of them vomited; 3
of the 4 who vomited did so for up to 6 h after fentanyl administration
(Scamman et al., 1984). Dizziness was reported by one additional
subject, who remained prone for 8 h after drug administration
(Scamman et al., 1984). It is not surprising that drug-inexperienced
individuals would not report liking the effects of fentanyl.
5.3. Illicit opioid users – reinforcing effects
In addition to evaluating subjective responses following drug ad-
ministration, the abuse potential of drugs in humans can be assessed by
self-administration procedures (Comer et al., 2008, 2012; Haney and
Spealman, 2008; Jones and Comer, 2013). Typically, participants are
asked to make a response (such as finger presses on a computer mouse)
in order to obtain drug, and a drug that is self-administered more than
placebo is considered to be a reinforcer. One procedure for assessing the
reinforcing effects of a drug uses a modified drug versus money pro-
gressive ratio schedule to assess reinforcing effects. Participants first
receive a sample dose of drug and money and then during a later ses-
sion, they have 10 opportunities to choose between 1/10th of the dose
or money that was sampled previously. Each time drug or money is
chosen, the number of responses (finger presses) progressively increases
and the point at which responding stops is termed the “break point” (it
is the highest ratio completed for drug and/or money). In morphine-
dependent individuals, 250 μg/70 kg i.v. fentanyl produced a pro-
gressive-ratio break point value for drug that was significantly greater
than placebo and similar to 12.5 mg/70 kg i.v. heroin, 25mg/70 kg i.v.
oxycodone, and 25mg/70 kg i.v. morphine (Comer et al., 2008). Fen-
tanyl also served as a reinforcer in methadone-maintained individuals
(Greenwald and Roehrs, 2004).
Another way of assessing drug self-administration is through “be-
havioral economic” procedures (Bickel et al., 1993, 1995; Hursh, 1993).
A re-analysis of data was performed from studies using a multiple-
choice procedure (in which subjects made a series of choices between
receiving a given drug dose and a range of money amounts; Greenwald,
2008; Griffiths et al., 1993). In this behavioral economic analysis of
multiple-choice procedure data, “demand curves” were constructed by
plotting drug choices as a function of unit price (response requirement
divided by dose) for fentanyl, hydromorphone, and methadone
(Greenwald, 2008). The demand curve for fentanyl was the most “in-
elastic” of the opioids that were tested, suggesting that fentanyl self-
administration was the most resistant to change when unit price in-
creases. However, several procedural differences across the studies
from which the analysis was derived might have accounted for this
finding, such as differences in route and method of drug administration
(i.v. fentanyl cumulative dosing versus intramuscular hydromorphone
acute dosing). Therefore, interpretation of the elasticity of fentanyl
relative to the other opioids should be made with caution.
Another interesting study that examined the reinforcing effects of
fentanyl was one in which recreational drug users (only one of whom
reported recreational use of opioids) were asked to immerse their
forearm in water maintained at different temperatures (37 °C, 10 °C,
and 2 °C; Zacny et al., 1996b). For each of the temperatures, partici-
pants completed two consecutive sampling trials and three consecutive
choice trials. They were instructed to choose one of the two infusion
pumps (containing either saline or 50 μg i.v. fentanyl) five minutes
before immersion of the forearm into the water. Under these conditions,
fentanyl was self-administered significantly more than placebo under
the two cold water conditions (77% of the time under both the 10 °C
and 2 °C conditions) but not when the water was maintained at 37 °C
(fentanyl was chosen 60% of the time, which did not differ from
chance). The presence of pain also altered the subjective effects of
fentanyl: participants reported feeling more elated after fentanyl ad-
ministration compared to saline in the 37 °C condition, but not when
they were asked to immerse their forearm in cold water (the 10 °C and
2 °C conditions). Some of these results were replicated in a subsequent
study: oxycodone was self-administered only in the presence of a
painful stimulus (hand immersions in water maintained at 2 °C), com-
pared to a non-painful stimulus (hand immersions in water maintained
at 37 °C; Comer et al., 2010). However, this outcome only occurred in
participants who had used prescription opioids medically but had never
used them recreationally. The participants who used prescription
opioids recreationally self-administered oxycodone regardless of the
presence or absence of pain (the 4 °C and 37 °C conditions). And unlike
the results reported by Zacny et al. (1996b), the positive subjective
responses produced by oxycodone did not differ in the presence and
absence of pain in either group. Thus, the lack of reinforcing effects of
fentanyl in the absence of pain in the study conducted by Zacny et al.
(1996b) may have been due to the fact that the participants were not
recreational users of opioids.
The studies reviewed above highlight several important factors that
must be considered when evaluating and interpreting results of abuse
potential studies in humans, including the population selected for study
(recreational opioid users should be examined), the assessment time
points used (they should capture the expected pharmacokinetic profile
of the drug, especially at early time points after drug administration),
and the use of behavioral endpoints such as drug self-administration to
provide greater clarity on the abuse liability of a drug. When all of these
factors are considered, the pharmacological profile of fentanyl suggests
that it has high potential for abuse in humans. However, the abuse
liability of fentanyl relative to other mu opioid agonists remains
somewhat unclear. The analysis by Greenwald (2008) suggests that
fentanyl might have greater abuse liability than hydromorphone and
methadone, but procedural inconsistencies in the studies that were
examined make definitive conclusions difficult. The study by Comer
et al. (2008) showed that fentanyl is more potent than heroin,
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morphine, and oxycodone, but it has similar abuse liability as the other
drugs. In that study, testing higher doses of fentanyl and using higher
progressive ratio values to avoid ceiling effects would have been
helpful. Future studies using potentially more sensitive measures, such
as a drug versus drug choice procedure or prospective assessments of
demand curves for fentanyl compared to other mu opioids would be
informative. Another way of approaching this issue is by asking opioid
users directly how they perceive the effects of fentanyl. Cicero et al.,
2017 asked 10,900 individuals who were entering treatment for opioid
use disorder about fentanyl. This analysis was hampered by several
variables, however, including the fact that both commercial and illicit
fentanyl products are available to users and it is impossible to distin-
guish among them based on urine drug screens, illicit fentanyl is most
often added to heroin and other drugs unbeknownst to the user, and the
extent to which illicit fentanyl alone is available to users and sought out
by them is unclear. Given the current patterns of illicit manufacturing,
modern marketing techniques, and enormous profits to be made,
however, it is likely that illicit fentanyl use will become even more
widespread in the years to come (DEA Intelligence Brief DEA-DCT-DIB-
021-16, 2016; Gilbert and Dasgupta, 2017).
6. Implications for treatment of illicit fentanyl use
The preclinical data reviewed above support the view that the
pharmacology of fentanyl differs from other mu opioid agonists such as
morphine. In contrast, it is unclear whether the pharmacology of fen-
tanyl in humans as it relates to abuse liability differs significantly from
other mu opioids, in part because the research procedures that could
potentially make this differentiation (e.g., a drug versus drug choice
paradigm or prospective behavioral economics procedures) have not
been applied to this question. Whether the pharmacology of fentanyl in
humans as it relates to toxicity differs from other opioids has also been
understudied, even though the toxicity of fentanyl in clinical settings
has been well characterized. While it is well known that fentanyl, like
other opioid agonists, produces respiratory depression primarily via
activation of opioid receptors in the pre-Bötzinger complex as well as
actions in the Kolliker-Fuse and parabrachial nuclei of the pons (Lalley,
2006), recent clinical studies have also demonstrated that fentanyl in-
duces chest wall rigidity that may contribute to fatalities (Burns et al.,
2016). Further, the combination of fentanyl with other drugs of abuse
or CNS depressants such as alcohol likely engages additional mechan-
isms, including cardiac arrhythmias, that lead to mortality. The
knowledge gap in how fentanyl may differ from other opioid agonists is
mainly due to the fact that fentanyl is used in a very different manner
by a clinician administering the drug to a patient compared to a drug
user self-administering fentanyl for its euphoric effects (i.e., a large
bolus dose injected very rapidly, often in combination with alcohol or
other drugs of abuse such as cocaine or benzodiazepines).
In addition to the research gaps regarding the relative abuse liability
and toxicity of fentanyl compared to other opioid agonists, little in-
formation from controlled clinical trials is available about the effec-
tiveness of treatment medications (methadone, buprenorphine, nal-
trexone) in reducing illicit fentanyl use, or naloxone for treating
fentanyl-related overdose. Preclinical studies have clearly established
that fentanyl interacts in a competitive manner with opioid antagonists
such as naltrexone (e.g., Comer et al., 1992; Cornelissen et al., 2018).
As such, simply increasing the antagonist dose should be effective if the
euphoric effects of fentanyl are not completely suppressed (naltrexone)
or the respiratory depressant effects of fentanyl are not completely re-
versed (naloxone). An important caveat to the latter statement is that
the effectiveness of naloxone in reversing fentanyl-related overdoses is
not clear when alcohol or other drugs have been co-ingested with
fentanyl or if a synthetic fentanyl-like drug has been used.
Naloxone has been used for decades to reverse opioid-induced re-
spiratory depression in both hospital (e.g., during surgery) and non-
hospital settings (e.g., overdose by an illicit drug user). It has a rapid
onset (within 2min following intravenous administration) and short
serum half-life (∼1 h). In opioid-dependent individuals, naloxone can
precipitate withdrawal, the severity of which may depend on multiple
factors, such as the individual’s level of physical dependence, the
amount and type of opioid agonist used during the overdose event, the
time between the overdose event and administration of naloxone, and
the amount of naloxone used to reverse the overdose. In order to avoid
precipitating severe withdrawal, the American Heart Association re-
commends starting with a small dose of naloxone (0.4 mg in-
tramuscularly or 2mg intranasally). However, recent reports suggest
that higher doses or repeated dosing of naloxone (due to recurrence of
respiratory depression) may be required to reverse fentanyl-induced
respiratory depression (Fairbairn et al., 2017; Lynn and Galinkin, 2018;
Somerville et al., 2017). The reason that higher doses of naloxone may
be required is not entirely clear. Possibilities are that a large dose of
naloxone is needed simply because a large dose of fentanyl was used, a
fentanyl analog was used that is not sensitive to naloxone, or, because
the onset of fentanyl-induced respiration is so rapid, the naloxone was
administered after the individual was already deceased. Another pos-
sibility is that fentanyl and naloxone may share an influx transporter
into the brain and that when high doses of fentanyl are used, the
transporter becomes saturated, so naloxone is not able to cross the
blood-brain barrier (Lynn and Galinkin, 2018; Suzuki et al., 2010).
Clearly, there is a dire need for more clinical studies to assess the ef-
fectiveness of naloxone in reversing respiratory depression induced by
fentanyl and synthetic fentanyl-like drugs following various routes of
administration (Fairbairn et al., 2017; Somerville et al., 2017).
The effectiveness of buprenorphine or methadone in reducing abuse
of fentanyl by humans is also largely unknown. Studies conducted in
rats have demonstrated that maintenance on buprenorphine was less
effective in reducing the analgesic effects of opioid agonists with lower
efficacy (morphine) compared to higher efficacy (etonitazene; Walker
and Young, 2001). A study also was conducted in rhesus monkeys
comparing the reinforcing effects of different opioid agonists in the
presence and absence of morphine physical dependence (e.g., Winger
and Woods, 2001). Through the mechanism of cross-tolerance, one
would expect a rightward shift in the dose-effect curves for opioids
when animals are physically dependent on morphine compared to no
dependence. Although this outcome was demonstrated for most of the
agonists tested, the rightward shift in the dose-effect curve for the
higher efficacy agonist alfentanil was smaller than for the intermediate
efficacy agonists, morphine and heroin. And the dose-effect curves for
the lower efficacy agonists were shifted either downward (buprenor-
phine) or rightward to a much greater extent (nalbuphine) than the
higher efficacy agonists (Winger and Woods, 2001). This pattern of
effects has been demonstrated in several different species (rats, mice,
monkeys, pigeons) across several different experimental assays (an-
algesia, drug discrimination, schedule-controlled responding for food,
self-administration; Barrett et al., 2001, 2003; Duttaroy and Yoburn,
1995; Negus et al., 2003; Paronis and Holtzman, 1992, 1994; Pitts
et al., 1998; Smith and Picker, 1998; Walker and Young, 2001, 2002;
Walker et al., 1995, 1998; Winger and Woods, 2001; Young et al.,
1991). Therefore, for both buprenorphine and opioid agonist main-
tenance, the general finding is that the effects of higher efficacy ago-
nists are more difficult to block than lower efficacy agonists. To the
extent that these findings can be extrapolated to humans, the data
suggest that methadone and buprenorphine may be less effective in
treating fentanyl abuse than it is in treating heroin abuse.
In sum, a great deal is known about the pharmacology of fentanyl
using preclinical models and when it is used therapeutically in humans
for anesthesia or analgesia. However, studies are desperately needed to
elucidate the physiological mechanisms underlying fentanyl overdose
so that effective treatments can be developed to reduce the risk of
death. Similarly, studies to evaluate the most effective maintenance
doses and dosing regimens of naltrexone, methadone, and buprenor-
phine for treating fentanyl abuse are urgently needed to address the
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public health crisis posed by use of illicit fentanyl.
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